Rin­voq pass­es PhI­II main­te­nance study for Crohn's dis­ease, po­ten­tial­ly set­ting the stage for la­bel ex­pan­sion

Af­ter Ab­b­Vie’s Rin­voq first got ap­proved back in 2019, JAK in­hibitors have been cloud­ed by nu­mer­ous safe­ty is­sues and events, like with ri­val Pfiz­er’s Xel­janz. Now with the newest study out of Ab­b­Vie, there might be room to fol­low the route its sales king Hu­mi­ra did — ex­pand­ing the drug in­to oth­er in­di­ca­tions and calm­ing con­cerns about the drug class.

Ab­b­Vie an­nounced top-line re­sults ear­li­er this week from a Phase III study for upadac­i­tinib, its JAK in­hibitor that had been pre­vi­ous­ly ap­proved for rheuma­toid arthri­tis. The study, called U-EN­DURE, was a 52-week main­te­nance study in adults with mod­er­ate to se­vere Crohn’s dis­ease “who had an in­ad­e­quate re­sponse or were in­tol­er­ant to a con­ven­tion­al or bi­o­log­ic ther­a­py.” Rin­voq met the co-pri­ma­ry end­points of en­do­scop­ic re­sponse and clin­i­cal re­mis­sion, as well as the sec­ondary end­point of en­do­scop­ic re­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER